Bruce H. Morimoto
Direktor/Vorstandsmitglied bei Safety Pharmacology Society
Profil
Bruce H.
Morimoto is currently the Director at Safety Pharmacology Society.
He previously worked as Director-Business Development at Phoenix International Life Sciences, Director-Drug Development at Neuromed Pharmaceuticals Ltd., Program Director at MDS Pharma Services (Canada), Director-Research & Development at AMUR Pharmaceuticals, Vice President-Drug Development at Cerecin, Inc., and Vice President-Drug Development at Allon Therapeutics, Inc. He received his undergraduate and doctorate degrees from the University of California, Los Angeles.
Aktive Positionen von Bruce H. Morimoto
| Unternehmen | Position | Beginn |
|---|---|---|
| Safety Pharmacology Society | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Bruce H. Morimoto
| Unternehmen | Position | Ende |
|---|---|---|
Cerecin, Inc.
 Cerecin, Inc. Pharmaceuticals: MajorHealth Technology Cerecin, Inc. develops therapies to treat central nervous system disorders. It offers therapeutic treatments for Parkinson's disease, Alzheimer's disease, and other age-related memory loss disorders. The firm is also developing therapies that address metabolic deficiencies and provide an alternative energy source for brain cells. The company was founded in 2001 and is headquartered in Boulder, CO. | Corporate Officer/Principal | - |
Neuromed Pharmaceuticals Ltd.
 Neuromed Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Neuromed Pharmaceuticals Ltd. develops chronic pain drugs. Its NMED-1077 product is an extended release formulation of hydromorphone in phase 3 clinical development. It conducts research for drugs to cure anxiety, epilepsy, hypertension, and cardiovascular diseases. The company was founded by Dr. Terrance P. Snutch in 1998 and is headquartered in Vancouver, BC. | Corporate Officer/Principal | - |
MDS Pharma Services (Canada)
 MDS Pharma Services (Canada) Miscellaneous Commercial ServicesCommercial Services MDS Pharma Services provides contract drug discovery and drug development services for pharmaceutical and biotechnology companies. It provides its clients with early-stage, clinical research and late-stage drug discovery and development services, such as Phase I-IV testing, target discovery and lead optimization. The company is located in Saint-Laurent, Canada. | Corporate Officer/Principal | - |
| AMUR Pharmaceuticals, Inc. | Technik-/Wissenschafts-/F&E-Leiter | - |
Phoenix International Life Sciences, Inc.
 Phoenix International Life Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sotera Health Co., Phoenix International Life Sciences, Inc. is a Canadian company that provides bioanalytical research and clinical testing services. The company is based in Saint-Laurent, Canada. Phoenix International Life Sciences was acquired by Nordion (Canada), Inc., part of Sotera Health Co. from July 30, 2018 on May 22, 2000 for $236.74 million. | Corporate Officer/Principal | - |
Ausbildung von Bruce H. Morimoto
| University of California, Los Angeles | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ALLON THERAPEUTICS INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
Phoenix International Life Sciences, Inc.
Phoenix International Life Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sotera Health Co., Phoenix International Life Sciences, Inc. is a Canadian company that provides bioanalytical research and clinical testing services. The company is based in Saint-Laurent, Canada. Phoenix International Life Sciences was acquired by Nordion (Canada), Inc., part of Sotera Health Co. from July 30, 2018 on May 22, 2000 for $236.74 million. | Commercial Services |
Cerecin, Inc.
Cerecin, Inc. Pharmaceuticals: MajorHealth Technology Cerecin, Inc. develops therapies to treat central nervous system disorders. It offers therapeutic treatments for Parkinson's disease, Alzheimer's disease, and other age-related memory loss disorders. The firm is also developing therapies that address metabolic deficiencies and provide an alternative energy source for brain cells. The company was founded in 2001 and is headquartered in Boulder, CO. | Health Technology |
Neuromed Pharmaceuticals Ltd.
Neuromed Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Neuromed Pharmaceuticals Ltd. develops chronic pain drugs. Its NMED-1077 product is an extended release formulation of hydromorphone in phase 3 clinical development. It conducts research for drugs to cure anxiety, epilepsy, hypertension, and cardiovascular diseases. The company was founded by Dr. Terrance P. Snutch in 1998 and is headquartered in Vancouver, BC. | Health Technology |
MDS Pharma Services (Canada)
MDS Pharma Services (Canada) Miscellaneous Commercial ServicesCommercial Services MDS Pharma Services provides contract drug discovery and drug development services for pharmaceutical and biotechnology companies. It provides its clients with early-stage, clinical research and late-stage drug discovery and development services, such as Phase I-IV testing, target discovery and lead optimization. The company is located in Saint-Laurent, Canada. | Commercial Services |
| AMUR Pharmaceuticals, Inc. | |
| Safety Pharmacology Society |
